Central nervous system involvement in multiple myeloma is a rare complication but carries a
very poor prognosis. We provide a review of current literature, including presentation …

Pomalidomide is a potent immunomodulatory agent that is currently a standard of care
backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory …

Central nervous system localization of multiple myeloma (CNS-MM) accounts for about 1%
of all MM during disease course or even rarer at diagnosis. A difference in the origin, ie …

Objectives: Myelomatous pleural effusion is a rare presentation of extramedullary disease in
multiple myeloma, which has been reported with dismal prognosis. We aimed to explore …

After relapse or progression of the CNS-MM disease, four of the 13 (31%) patients continued
to receive second-line therapy for CNS-MM and one of 13 (8%) a third-line therapy …

Few reports have so far described central nervous system (CNS) involvement in multiple
myeloma (MM), which shows a poor prognosis owing to its resistance to several treatments …

Patients with multiple myeloma (MM) rarely present with central nervous system (CNS)
involvement as a manifestation of extramedullary disease (EMD), a condition that is …

Aim: Daratumumab, a CD38 monoclonal antibody, has been widely used in patients with
multiple myeloma. Although a variety of adverse events have been reported, consciousness …

Background: Extranodal natural killer/T-cell lymphoma (ENKL) is a rare subtype of mature T
and natural killer cell lymphomas associated with Epstein-Barr virus. Case: A 20-year-old …

A 60-year-old male was referred for headache, dizziness, nausea, and fatigue in May 2021.
White blood cell count was 7.2× 109∕ L; hemoglobin was 64 g/L; and platelets were 38× …